IRONWOOD PHARMACEUTICALS, INC. Proceeds and Excess Tax Benefit from Share-based Compensation
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Proceeds and Excess Tax Benefit from Share-based Compensation of $945.00 thousand for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-10.
Discontinued › Notes › Compensation Related Costs
us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation · last filed 2012-05-10
- IRONWOOD PHARMACEUTICALS, INC. proceeds and excess tax benefit from share-based compensation for the quarter ending 2012-03-31 was $945.00K, a 40.00% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. proceeds and excess tax benefit from share-based compensation for the quarter ending 2011-03-31 was $675.00K.
| Period end | Proceeds and Excess Tax Benefit from Share-based Compensation 3 month |
|---|---|
| 2012-03-31 | $945.00K 10-Q · filed 2012-05-10 |
| 2011-03-31 | $675.00K 10-Q · filed 2012-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |